Your health matters to us
An overarching goal of the National Health Co-op is to significantly reduce instances of preventable diseases and lessen the personal and societal impact of chronic conditions. That’s why we regularly review our patients’ files to identify individuals who may benefit from additional clinical support.
Hepatitis C is a blood-borne virus that causes inflammation (swelling and pain) of the liver. This virus is present in the blood of an infected person and can be spread through blood-to-blood contact.
A greater understanding of the hepatitis C virus has enabled efforts to improve efficacy and tolerability of treatment for the virus. Notably, this has led to the development of multiple direct-acting antivirals (DAAs), which are medications targeted at specific steps within the virus life cycle.
These medications now are available to Australians living with chronic hepatitis C. This is a leap forward in the management and treatment of hepatitis C and positions Australia as a world leader in publicly-funded access to these new, highly effective medicines.
The DAA medicines are:
- more effective, resulting in a cure for 90-95% of people
- taken as tablets only with very few side-effects
- taken for as little as 8-12 weeks in most cases
- interferon-free for most people
DAA medicines available on the PBS from 1 January 2017 include:
- Daklinza® (daclatasvir)
- Harvoni® (sofosbuvir + ledipasvir)
- Ibavyr® (ribavirin)
- Sovaldi® (sofosbuvir)
- Viekira Pak® (paritaprevir + ritonavir + ombitasvir + dasabuvir)
- Viekira Pak RBV® (paritaprevir + ritonavir + ombitasvir + dasabuvir + ribavirin)
- Zepatier® (grazoprevir + elbasvir)
The new DAA medicines are available through the PBS for all people living with hepatitis C who are over the age of 18 and hold a Medicare card.